Chief Executive Officer
Mr. Riley has more than 25 years of experience in the biotechnology and pharmaceutical industries, during which he has negotiated numerous worldwide strategic corporate alliances, established joint ventures and assisted in venture financings to support product development. He has raised over $1.5B in equity and debt instruments. He has worked for big pharma (SmithKline, Beecham, and Pfizer), Diagnostics (Nichols Institute, Quest Diagnostics (NYSE:DGX), and Nexgen), venture capital (Queensland Biocapital Fund / QIC, 526 Ventures) and numerous biotechnology companies (AvMax, Ontogen, Amphora, Xenome, Telesso, HUYA, etc.). Mr. Riley has served on public and private Boards in the USA and Australia in the capacity as Chairman, Audit Committee, Compensation Committee and Nominating Committee fiduciary. Further, Mr. Riley has served in various executive capacities including CEO, CBO, CFO, COO, and EVP of Business Development for both private and public biotechnology, diagnostic, and pharmaceutical companies.
Mr. Riley’s scientific expertise encompasses various disease states that include gastrointestinal disorders, central nervous system disorders, oncology, inflammation, and the microbiome. Within these disease states, Mr. Riley has driven forward commercial products for proteins, small molecules, exosomes, microbiome manipulation and monoclonal antibodies.
Mr. Riley earned his Masters of International Management degree from the Thunderbird School of Global Management, his MBA in Accounting and Finance from Arizona State University’s W.P. Carey School of Business, and the completion of advanced pharmacokinetics, drug discovery and ADMET development courses from the University of California, San Francisco School of Medicine.